Inhibitors of C5a for the treatment of viral pneumonia
The present invention relates to inhibitors of C5a for use in the treatment of pneumonia, especially viral pneumonia. The invention also relates to the use of inhibitors of C5a in the preparation of a pharmaceutical composition for the treatment of pneumonia, especially viral pneumonia. The inventors further relates to methods for the treatment of pneumonia, especially viral pneumonia, comprising the step of administering a therapeutic amount of an inhibitor of C5a to a subject in need thereof.
1. A method for the reduction of viral load in a subject suffering from viral pneumonia caused by an HxNx influenza virus, said method comprising the step of: administering a therapeutic amount of an inhibitor of C5a to said subject, thereby reducing viral load in said subject, wherein the inhibitor of C5a is a binding moiety specifically binding to human C5a, wherein said binding moiety specifically binds to a conformational epitope formed by amino acid sequences NDETCEQRA (SEQ ID NO: 2) and SHKDMQL (SEQ ID NO: 3) of human C5a, wherein the binding moiety binds to at least one amino acid within the amino acid sequence according to SEQ ID NO: 2 and to at least one amino acid within the amino acid sequence according to SEQ ID NO: 3, and wherein said binding moiety is an antibody or an antigen-binding fragment thereof.
2. The method according to claim 1 , wherein the HxNx influenza virus is selected from the group consisting of H1N1, H1N3, H2N2, H3N2, H5N1, H7N2, H7N3, H7N7, H7N9, H9N2, H10N7, and H10N8.
3. The method according to claim 1 , wherein the subject is a human.
4. The method according to claim 1 , wherein said binding moiety is an antibody or an antigen-binding fragment thereof,
wherein said antibody or antigen-binding fragment thereof comprises
(i) a heavy chain CDR3 sequence as set forth in SEQ ID NO: 6; or
(ii) a heavy chain CDR3 sequence as set forth in SEQ ID NO: 7.
5. The method according to claim 1 , wherein said binding moiety is an antibody or an antigen-binding fragment thereof,
wherein said antibody or antigen-binding fragment thereof comprises
(iii) a light chain CDR3 sequence as set forth in SEQ ID NO: 8; or
(iv) a light chain CDR3 sequence as set forth in SEQ ID NO: 9.
6. The method according to claim 1 , wherein said binding moiety is an antibody or an antigen-binding fragment thereof,
wherein said antibody or antigen-binding fragment thereof comprises at least one of the following sequences:
(v) a heavy chain CDR2 sequence according to SEQ ID NO: 10;
(vi) a heavy chain CDR2 sequence according to SEQ ID NO: 11;
(vii) a light chain CDR2 sequence according to SEQ ID NO: 12;
(viii) a light chain CDR2 sequence according to SEQ ID NO: 13;
(ix) a heavy chain CDR1 sequence according to SEQ ID NO: 14;
(x) a heavy chain CDR1 sequence according to SEQ ID NO: 15;
(xi) a light chain CDR1 sequence according to SEQ ID NO: 16; or
(xii) a light chain CDR1 sequence according to SEQ ID NO: 17.